BIIB - BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Case | Benzinga
SAN DIEGO, July 13, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ:BIIB) securities between February 3, 2022 and February 13, 2024, all dates inclusive (the "Class Period"), have until July 22, 2024 to seek appointment as lead plaintiff in the Biogen class action lawsuit. Captioned Gray v. Biogen Inc., No. 24-cv-01444 (D. Colo.), the Biogen class action lawsuit charges Biogen as well as certain of Biogen's top current and former executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Biogen class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-biogen-inc-class-action-biib.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Biogen class action lawsuit must be filed with the court no later than July 22, 2024.
CASE ALLEGATIONS: Biogen's products include, among others, Leqembi and Aduhelm for the treatment of Alzheimer's disease ("AD"), as well as various drugs for the treatment of multiple sclerosis.
The Biogen class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Biogen had overstated its efforts to enhance its transparency, corporate governance, and compliance controls and procedures, as well as the efficacy of those controls and procedures; (ii) accordingly, Biogen maintained inadequate compliance controls and procedures in connection with its business operations in foreign countries; (iii) Biogen and/or its employees were engaged in unlawful or otherwise improper conduct in several foreign countries; (iv) the foregoing subjected Biogen to a heightened risk of governmental and/or regulatory scrutiny and enforcement action, as well as significant legal, financial, and reputational harm; (v) Biogen overstated the strength of its AD-related product portfolio, including Biogen's and Eisai Co., Ltd.'s efforts and success in launching ...